First human test of experimental cancer therapy begins
NCT ID NCT05450562
Summary
This early-stage study tested a new drug called SAR444200, given alone or with other cancer medicines, in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors. The study was terminated early and enrolled 33 participants with specific cancers, including liver cancer and lung cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Icahn School of Medicine at Mount Sinai- Site Number : 8400005
New York, New York, 10029, United States
-
Investigational Site Number : 1240001
Québec, Quebec, G1R 2J6, Canada
-
Investigational Site Number : 1240002
Toronto, Ontario, M5G 2M9, Canada
-
Investigational Site Number : 1560001
Shanghai, 200120, China
-
Investigational Site Number : 1560002
Wuhan, 430022, China
-
Investigational Site Number : 4100001
Seoul, Seoul-teukbyeolsi, 06351, South Korea
-
Investigational Site Number : 4100002
Seoul, Seoul-teukbyeolsi, 05505, South Korea
-
Investigational Site Number : 7020001
Singapore, 308433, Singapore
-
Investigational Site Number : 7020002
Singapore, 119074, Singapore
-
Investigational Site Number : 7020003
Singapore, 169610, Singapore
-
Lifespan Corporation- Site Number : 8400002
Providence, Rhode Island, 02903, United States
-
The University of Texas MD Anderson Cancer Center- Site Number : 8400003
Houston, Texas, 77030, United States
-
USC Norris Comprehensive Cancer Center- Site Number : 8400004
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.